Tumorlets, Multicentric Carcinoids, Lymph-Nodal Metastases, and Long-Term Behavior in Bronchial Carcinoids

Ferollà, Piero; Daddi, Niccolò; Urbani, Moira; Semeraro, Antonia; Ribacchi, R; Giovenali, Paolo; Ascani, Stefano; Angelis, Verena De; Crinò, Lucio; Puma, Francesco; Daddi, G

doi:10.1097/jto.0b013e318197f2e7

Cited by 75 publications

(42 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected, the treatment (operation or non-operation) was an independent prognostic factor that influenced the survival of patients. Until now, only a few articles discussed the clinical treatment outcomes of NET (Lim et al, 2005;Asamura et al, 2006), and many scholars just cared about TC outcomes alone (Ferolla et al, 2009;Naalsund et al, 2011). In this study, there were 111 patients undergoing the surgical treatment, and the survival in operation group was significantly better than in non-operation group (P=0.000), suggesting that surgery is the cornerstone in the treatment of pulmonary NET.…”

Section: Discussionmentioning

confidence: 73%

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Hu²,

Sun³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 73%

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Hu²,

Sun³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…As in other MEN1 manifestations, multiplicity seems to be common in pulmonary carcinoids (Marx et al 1998, Sachithanandan et al 2005. In its sporadic counterpart, multiplicity is seen in !1-9% (Daddi et al 2004, Garcia-Yuste et al 2007, Ferolla et al 2009, Okoye et al 2013. Ectopic hormone production is not reported in MEN1-related pulmonary carcinoids, in contrast to sporadic disease (Boddaert et al 2012, Garby et al 2012, Simonds et al 2012.…”

Section: Natural History and Prognostic Factors: Pulmonary Carcinoidsmentioning

confidence: 99%

Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis

Pieterman¹,

Conemans²,

Dreijerink³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Mutations of the multiple endocrine neoplasia type 1 (MEN1) gene lead to loss of function of its protein product menin. In keeping with its tumor suppressor function in endocrine tissues, the majority of the MEN1-related neuroendocrine tumors (NETs) show loss of heterozygosity (LOH) on chromosome 11q13. In sporadic NETs, MEN1 mutations and LOH are also reported, indicating common pathways in tumor development. Prevalence of thymic NETs (thNETs) and pulmonary carcinoids in MEN1 patients is 2-8%. Pulmonary carcinoids may be underreported and research on natural history is limited, but disease-related mortality is low. thNETs have a high mortality rate. Duodenopancreatic NETs (dpNETs) are multiple, almost universally found at pathology, and associated with precursor lesions. Gastrinomas are usually located in the duodenal submucosa while other dpNETs are predominantly pancreatic. dpNETs are an important determinant of MEN1-related survival, with an estimated 10-year survival of 75%. Survival differs between subtypes and apart from tumor size there are no known prognostic factors. Natural history of nonfunctioning pancreatic NETs needs to be redefined because of increased detection of small tumors. MEN1-related gastrinomas seem to behave similar to their sporadic counterparts, while insulinomas seem to be more aggressive. Investigations into the molecular functions of menin have led to new insights into MEN1-related tumorigenesis. Menin is involved in gene transcription, both as an activator and repressor. It is part of chromatin-modifying protein complexes, indicating involvement of epigenetic pathways in MEN1-related NET development. Future basic and translational research aimed at NETs in large unbiased cohorts will clarify the role of menin in NET tumorigenesis and might lead to new therapeutic options.

show abstract

“…PC is diagnosed in up to 5% of patients with multiple endocrine neoplasia type 1 (MEN1) [39-42]. Follow-up of a prospective cohort of MEN1 patients, with primary hyperparathyroidism and negative whole-body imaging, is expected to clarify the exact incidence of PCs in patients with MEN1 (NCT03348501).…”

Section: Classification and Diagnosticsmentioning

confidence: 99%

Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms

et al. 2018

View full text Add to dashboard Cite

Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

show abstract

Tumorlets, Multicentric Carcinoids, Lymph-Nodal Metastases, and Long-Term Behavior in Bronchial Carcinoids

Cited by 75 publications

References 28 publications

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis

Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms

Contact Info

Product

Resources

About